Pharmacological treatments of COVID-19

Pharmacol Rep. 2020 Dec;72(6):1446-1478. doi: 10.1007/s43440-020-00152-9. Epub 2020 Aug 20.

Abstract

The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.

Keywords: COVID-19; Pharmacology; Pneumonia; SARS-CoV2.

Publication types

  • Review

MeSH terms

  • Animals
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic
  • Humans
  • SARS-CoV-2 / isolation & purification*